Neogenomics, Inc.
NEO
$10.10
$0.323.27%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 11.90% | 10.23% | 7.55% | 10.57% | 10.44% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 11.90% | 10.23% | 7.55% | 10.57% | 10.44% |
| Cost of Revenue | 15.50% | 13.55% | 4.43% | 7.71% | 3.68% |
| Gross Profit | 7.43% | 6.02% | 11.88% | 14.31% | 20.17% |
| SG&A Expenses | 11.45% | 15.39% | 5.66% | 9.75% | 2.75% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 13.59% | 14.42% | 6.21% | 8.79% | 4.53% |
| Operating Income | -33.77% | -51.81% | 1.22% | 7.35% | 36.23% |
| Income Before Tax | -47.85% | -140.92% | 7.31% | -5.51% | 16.79% |
| Income Tax Expenses | 593.33% | -93.07% | 142.90% | 16.25% | 94.89% |
| Earnings from Continuing Operations | -53.28% | -141.88% | 4.21% | -6.97% | 4.41% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -53.28% | -141.88% | 4.21% | -6.97% | 4.41% |
| EBIT | -33.77% | -51.81% | 1.22% | 7.35% | 36.23% |
| EBITDA | -161.15% | -3,169.21% | -1.97% | 90.44% | 199.31% |
| EPS Basic | -51.58% | -138.92% | 5.17% | -5.89% | 5.36% |
| Normalized Basic EPS | -67.80% | -66.75% | -0.48% | 2.62% | 45.06% |
| EPS Diluted | -50.93% | -134.93% | 5.17% | -5.89% | 6.67% |
| Normalized Diluted EPS | -67.80% | -66.75% | -0.48% | 2.62% | 45.06% |
| Average Basic Shares Outstanding | 1.15% | 1.22% | 1.00% | 0.98% | 1.01% |
| Average Diluted Shares Outstanding | 1.15% | 1.22% | 1.00% | 0.98% | 1.01% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |